Literature DB >> 24672102

Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study.

Daisy Carbajal1, Maria de Lourdes Arruzazabala1, Más Rosa1, Vivian Molina1, Eduardo Rodríguez1, Victor González1.   

Abstract

BACKGROUND: Benign prostatic hypertrophy is the nonmalignant, uncontrolled growth of prostatic epithelial cells and stroma that, left untreated, may lead to difficult urination and other complications. A common treatment of BPH is lipid extract from saw palmetto fruit, and lipid extract from Cuban Royal palm (a palm of the same family) fruit is being studied for this use. One study found that the latter, D-004, at 100 to 400 mg/kg daily prevented prostatic hypertrophy (PH) induced with testosterone (T) in a rat model.
OBJECTIVES: This study comprised 2 experiments in a rat model. The first assessed the effects of different doses of D-004 on T-induced PH; the second investigated the effects of D-004 on PH induced with dihydrotestosterone (DHT).
METHODS: In experiment 1, rats were distributed in 6 groups of 10 rats each. One group received an SC injection of soy oil and oral treatment with Tween 65/water vehicle (negative control). The other 5 groups received an SC injection of T 3 mg/kg daily and oral treatment with vehicle (positive control) or D-004 at 50, 200, 400, or 800 mg/kg daily suspended in vehicle. In experiment 2, rats were distributed in 3 groups of 10 rats each. A negative control group received treatment as in experiment 1. Positive controls received an SC injection of DHT 1.5 mg/kg and vehicle orally. The third group received an SC injection of DHT and oral treatment with D-004 at 800 mg/kg suspended in vehicle. All treatments were given for 14 days. At sacrifice, prostates were removed and weighed. Mean prostatic weights and prostatic/body weight ratios were calculated.
RESULTS: In experiment 1, in the groups receiving D-004 at 200, 400, or 800 mg/kg daily, prostatic weight was significantly lower compared with the positive control group (P < 0.05, P < 0.01, and P < 0.001, respectively); this effect was not seen in the group receiving 50 mg/kg daily. In the groups receiving D-004 at 400 and 800 mg/kg daily, prostatic/body weight ratio was significantly lower compared with positive controls (both, P < 0.05); this effect was not seen in the groups receiving 50 or 200 mg/kg daily. In experiment 2, prostatic weight and prostatic/body weight ratio in the group receiving D-004 were similar to those of positive controls. Body weight was not affected in any of the groups receiving D-004.
CONCLUSIONS: This study of rats with T- or DHT-induced PH suggests that D-004 at 200 to 800 mg/kg daily administered orally prevents T-induced PH, and that D-004 at 800 mg/kg daily does not prevent DHT-induced PH.

Entities:  

Keywords:  benign prostatic hypertrophy; dihydrotestosterone; prostatic enlargement; testosterone

Year:  2004        PMID: 24672102      PMCID: PMC3964564          DOI: 10.1016/j.curtheres.2005.01.001

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  30 in total

Review 1.  Development of a new in vitro model for the study of benign prostatic hyperplasia.

Authors:  F K Habib; M Ross; C W Bayne
Journal:  Prostate Suppl       Date:  2000

Review 2.  Benign prostatic hyperplasia.

Authors:  M J Barry; C G Roehrborn
Journal:  BMJ       Date:  2001-11-03

Review 3.  The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.

Authors:  Jaspreet S Sandhu; Alexis E Te
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

4.  FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostates.

Authors:  O Nakayama; J Hirosumi; N Chida; S Takahashi; K Sawada; H Kojo; Y Notsu
Journal:  Prostate       Date:  1997-06-01       Impact factor: 4.104

5.  Treatment of benign prostatic hyperplasia with phytosterols.

Authors:  B E Carbin; B Larsson; O Lindahl
Journal:  Br J Urol       Date:  1990-12

6.  Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up.

Authors:  John S Lam; Nicholas A Romas; Franklin C Lowe
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

7.  Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene.

Authors:  J P Deslypere; M Young; J D Wilson; M J McPhaul
Journal:  Mol Cell Endocrinol       Date:  1992-10       Impact factor: 4.102

Review 8.  A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same?

Authors:  J Irani; C T Brown; J van der Meulen; M Emberton
Journal:  BJU Int       Date:  2003-12       Impact factor: 5.588

9.  Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.

Authors:  L Rhodes; R L Primka; C Berman; G Vergult; M Gabriel; M Pierre-Malice; B Gibelin
Journal:  Prostate       Date:  1993       Impact factor: 4.104

10.  The role of dihydrotestosterone in benign prostatic hyperplasia.

Authors:  Culley Carson; Roger Rittmaster
Journal:  Urology       Date:  2003-04       Impact factor: 2.649

View more
  8 in total

1.  Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats.

Authors:  Chetan Nandecha; Alok Nahata; Vinod Kumar Dixit
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

2.  Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats.

Authors:  L Yohani Pérez; Roberto Menéndez; Rosa Más; Rosa M González
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

3.  In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.

Authors:  L Yohani Pérez; Roberto Menéndez; Rosa Má; Rosa M González
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

4.  Antioxidant effects of D-004, a lipid extract from the Roystonea regia fruit, on the plasma of healthy men.

Authors:  Ernesto López; Vivian Molina; José Illnait; Ambar Oyarzábal; Lilia C Fernández; Rosa Más; Rafael Gámez; Julio C Fernández; Sonia Jiménez; Meilis Mesa; Ivón Hollands; Sarahí Mendoza
Journal:  Asian J Androl       Date:  2009-01-26       Impact factor: 3.285

5.  Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.

Authors:  Lilia C Fernández; Rosa Mas; Julio Fernández; Sarahí Mendoza; Rafael Gámez; Balia Pardo
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

6.  Histomorphological effects of the oil extract of Sphenocentrum jollyanum seed on benign prostatic hyperplasia induced by exogenous testosterone and estradiol in adult Wistar rats.

Authors:  Godwin Mbaka; Steve Ogbonnia; Adeola Sulaiman; Daniel Osiagwu
Journal:  Avicenna J Phytomed       Date:  2019 Jan-Feb

7.  Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.

Authors:  Raúl Guzmán; Julio C Fernández; Manuel Pedroso; Lilia Fernández; José Illnait; Sarahí Mendoza; Ana T Quiala; Zunilda Rodríguez; Jilma Mena; Aylim Rodíguez; Marbelis Campos; Carlos Sánchez; Yanet Alvarez; Gladys Jiménez
Journal:  Ther Adv Urol       Date:  2019-06-11

8.  D-004 ameliorates phenylephrine-induced urodynamic changes and increased prostate and bladder oxidative stress in rats.

Authors:  Ambar Oyarzábal; Yohani Pérez; Vivian Molina; Rosa Mas; Yazmin Ravelo; Sonia Jiménez
Journal:  Transl Androl Urol       Date:  2015-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.